The market has witnessed significant growth in recent years, driven by advancements in gene editing technologies and increasing applications in healthcare and research. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of genetic engineering, enabling precise modifications to the genome for various purposes, including disease treatment, agriculture, and biotechnology.
Key factors contributing to the market growth include the rising prevalence of genetic disorders and chronic diseases, increasing investment in research and development activities, and growing awareness about personalized medicine. In addition, the adoption of CRISPR technology in agriculture for crop improvement and in industrial biotechnology for the production of biofuels and biochemicals is further propelling market expansion.
The Global CRISPR Gene Detection and Diagnostic Market will grow at a CAGR of 19.5% during the forecast period of 2022 to 2029.
Below are the Top Five CRISPR Gene Detection and Diagnostic Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific has a strong presence in the CRISPR gene detection and diagnostics market, providing innovative solutions for gene editing and genetic analysis. The company's products include CRISPR enzymes, kits, and reagents, as well as advanced instruments for gene detection and diagnostics. Thermo Fisher Scientific is known for its commitment to quality, innovation, and customer satisfaction, making it a trusted partner for researchers and healthcare professionals worldwide.
|
Life Sciences
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In December 2021, Thermo Fisher Scientific Inc. launched its new protein, Invitrogen TrueCut HiFi Cas9 Protein. The launch of the protein strengthened the CRISPR gene editing solutions platform and improved the market position
|
|
2.
|
Merck KGaA
|
In the CRISPR gene detection and diagnostic market, Merck KGaA offers a range of products and services that support gene editing, including CRISPR enzymes, kits, and reagents. The company is known for its innovative research and development efforts, focusing on delivering solutions that meet the evolving needs of researchers and healthcare professionals. Merck KGaA's strong global presence and dedication to scientific excellence make it a key player in the market.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In March 2022, Merck KGaA collaborated with an Israeli AgTech company to use CRISPR editing tools in the agriculture industry. The collaboration would allow the licensing of its foundational CRISPR intellectual property to Israeli BetterSeeds Ltd. This company uses genome editing technology, including CRISPR, to develop new breeds of plants. It would also increase the sales and distribution of the CRISPR editing tools and lead to marked revenue growth in the life sciences segment.
|
|
3.
|
Agilent Technologies, Inc.
|
In the CRISPR gene detection and diagnostic market, Agilent offers a range of products and solutions tailored to meet the needs of researchers and healthcare professionals. These include advanced instruments for gene editing and genetic analysis, as well as reagents and consumables for CRISPR experiments. With a focus on innovation, quality, and customer satisfaction, Agilent Technologies is a trusted partner in the field of molecular biology and genetic research.
|
CRISPR
CRISPR
• CRISPR Libraries
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In October 2016, Agilent Technologies, Inc. launched the SureGuide CRISPR Libraries for Functional Genomics. The SureGuide CRISPR Libraries for Functional Genomics enables CRISPR-based functional screening for any application. The launch strengthened the product portfolio and increased the supply and availability of the SureGuide CRISPR Libraries in biotechnology and academic and research institutes.
|
|
4.
|
Danaher
|
In the CRISPR gene detection and diagnostic market, Danaher offers a range of products and solutions through its Life Sciences segment, which includes businesses such as Beckman Coulter Life Sciences, Leica Biosystems, and Molecular Devices. These companies provide instruments, reagents, and software for gene editing, genetic analysis, and molecular diagnostics, catering to the needs of researchers and healthcare professionals. Danaher's focus on innovation, quality, and operational excellence makes it a prominent player in the market.
|
|
North America, Middle East and Africa, Europe, Asia-Pacific
|
In March 2021, Integrated DNA Technologies, Inc. launched the rhAmpSeq CRISPR Analysis System. The novel CRISPR analysis system delivers an end-to-end solution for researchers to check the specificity of CRISPR and other genome editing projects. The launch boosted the product range of CRISPR and Genome Editing and increased the market size of the CRISPR industry in North America, Europe, and Asia-Pacific regions.
|
|
5.
|
GenScript
|
In the CRISPR gene detection and diagnostic market, GenScript provides innovative solutions for gene editing and genetic analysis. The company's CRISPR products include CRISPR enzymes, kits, and reagents, as well as custom CRISPR services. With a focus on innovation, quality, and customer satisfaction, GenScript is dedicated to advancing the field of life sciences and making a positive impact on human health.
|
CRISPR gRNA Plasmids
CRISPR sgRNA Services
CRISPR gRNA Plasmids
CRISPR gRNA Plasmids
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In May 2021, GenScript formed an agreement with ERS Genomics Limited to access the CRISPR/Cas9 patent portfolio of ERS Genomics Limited. The agreement resulted in improving and strengthening GenScript’s CRISPR product and service offering for gene and cell therapy research across North America and the European region.
|
Conclusion
The CRISPR gene detection and diagnostic market is experiencing rapid growth and technological advancements, driven by increasing applications in healthcare, agriculture, and biotechnology. Despite challenges such as regulatory limitations and ethical concerns, the market is poised for continued expansion. The rising prevalence of genetic disorders and chronic diseases, along with the growing demand for personalized medicine, are key factors fueling market growth. Additionally, the adoption of CRISPR technology in agriculture and industrial biotechnology is further driving market expansion. Collaboration between academic institutions, research organizations, and biotechnology companies is expected to accelerate the development and commercialization of CRISPR-based products, paving the way for innovative solutions in gene editing and genetic analysis.
